Loading...
XKRX
214450
Market cap2.23bUSD
Apr 09, Last price  
321,000.00KRW
1D
0.31%
1Q
27.63%
Jan 2017
694.55%
IPO
182.57%
Name

PharmaResearch Co Ltd

Chart & Performance

D1W1MN
P/E
42.19
P/S
12.37
EPS
7,608.61
Div Yield, %
—
Shrs. gr., 5y
1.54%
Rev. gr., 5y
32.35%
Revenues
261.01b
+34.02%
37,454,866,93345,953,114,75754,469,757,89164,280,682,05683,871,642,044108,745,921,878154,082,897,894194,758,643,934261,010,910,560
Net income
76.55b
+88.66%
12,877,827,17213,909,058,67712,955,558,10714,408,301,97416,667,485,00432,774,330,37046,688,655,71040,576,699,24076,551,213,750
CFO
64.95b
+9.33%
16,022,957,5838,161,008,6038,643,379,0465,203,397,41819,273,230,95132,391,668,89065,297,140,55459,403,807,96664,945,249,410
Dividend
Dec 27, 2023660 KRW/sh
Earnings
May 12, 2025

Profile

PharmaResearch Co., Ltd. operates as a biopharmaceutical company in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; Rejuvenex cream, which treats the wound through rapid tissue regeneration; REJURAN HEALER, an intra dermal injection to enhance elasticity, turgidity, and tonicity of skin; Rejuran i and Rejuran s intra dermal or cannula injections; REJURAN moisturizer for daily skin protection; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel; REJURAN healing cream and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. It also provides D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; and CLEVIEL prime plus and contour plus with lidocaine medical devices, as well as CONJURAN medical devices. In addition, the company offers functional foods under the REJULINE, REJUSHINE, and REJULIGHT brands. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Seongnam, South Korea.
URL
http://pharmaresearch.co.kr/
IPO date
Jul 24, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
261,010,911
34.02%
194,758,644
26.40%
Cost of revenue
132,109,057
105,522,831
Unusual Expense (Income)
NOPBT
128,901,854
89,235,813
NOPBT Margin
49.39%
45.82%
Operating Taxes
23,439,915
10,613,904
Tax Rate
18.18%
11.89%
NOPAT
105,461,939
78,621,909
Net income
76,551,214
88.66%
40,576,699
-13.09%
Dividends
(7,529,103)
(6,315,548)
Dividend yield
0.65%
0.91%
Proceeds from repurchase of equity
359,235
BB yield
-0.03%
Debt
Debt current
33,006,061
20,574,144
Long-term debt
1,481,343
46,194,233
Deferred revenue
835,476
Other long-term liabilities
6,663,909
2,210,924
Net debt
(244,234,943)
(183,035,266)
Cash flow
Cash from operating activities
64,945,249
59,403,808
CAPEX
(12,062,682)
(17,757,766)
Cash from investing activities
(44,667,653)
(11,907,643)
Cash from financing activities
(25,968,629)
(9,301,361)
FCF
55,053,360
63,570,103
Balance
Cash
160,298,060
184,343,338
Long term investments
118,424,288
65,460,304
Excess cash
265,671,802
240,065,710
Stockholders' equity
304,560,417
234,324,630
Invested Capital
236,715,954
196,174,409
ROIC
48.72%
39.85%
ROCE
25.66%
20.55%
EV
Common stock shares outstanding
10,559
9,976
Price
109,500.00
56.65%
69,900.00
-14.76%
Market cap
1,156,238,094
65.81%
697,316,319
-15.41%
EV
957,343,523
542,434,045
EBITDA
140,897,450
99,982,856
EV/EBITDA
6.79
5.43
Interest
2,987,196
3,830,064
Interest/NOPBT
2.32%
4.29%